Dilip Shanghvi

Sun Pharma manufactures over 2,000 pharmaceutical products (across dosage forms including tablets, capsules, injectables, and topicals) marketed in over 100 countries. Sun Pharma's strategy has evolved beyond pure generics toward specialty pharmaceuticals: the company has built growing branded portfolios in dermatology (Ilumya/tildrakizumab for psoriasis, Winlevi for acne), ophthalmology, and oncology. These specialty products carry higher margins and longer product lifecycles than generic drugs, helping Sun Pharma reduce its dependence on the commoditized generic market where price competition is intense. India's pharmaceutical industry is the world's largest generic drug producer, supplying affordable medicines globally and benefiting from the continuous pipeline of patent expirations on branded drugs. Sun Pharma operates a global manufacturing network with facilities in India, the U.S., and other markets. Key stock drivers include U.S. generic drug pricing, specialty product launches and market uptake, India domestic market growth, ANDA (generic drug application) pipeline, manufacturing quality and FDA compliance, and the competitive dynamics with Teva, Mylan/Viatris, and other Indian generic companies.